TACAs Antibodies

Discover anti-TACA antibodies targeting tumor-associated carbohydrate antigens for cancer immunology and glycobiology research. RUO

Почему исследователи выбирают abinScience

Высокоспециализированные реагенты Purpose-built antibodies for niche research applications with validated performance data on every datasheet.

Строгая валидация применений Each antibody tested in relevant applications with supporting images and quantitative data.

Оригинальный производитель Developed and produced in-house — full traceability, batch consistency, and competitive pricing.

Экспертная техническая поддержка Application scientists available for reagent selection, protocol optimization, and troubleshooting.

Гибкие варианты Unconjugated and conjugated formats; bulk quantities and custom conjugation available on request.

Документы & данные контроля качества

Download product datasheets, валидационные изображения (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

Часто задаваемые вопросы

Как валидируются ваши антитела?

Every antibody is validated in its listed applications (WB, IHC, IF, ELISA, FC) with supporting images and data on the product page. We use positive and negative controls plus knockout/knockdown verification where available.

Предлагаете ли вы конъюгированные антитела?

Yes — HRP, AP, biotin, FITC, PE, APC, Alexa Fluor, and other fluorochrome conjugates are available. Custom conjugation services are also offered for bulk orders.

С какими видами реагируют ваши антитела?

Most antibodies target human, mouse, and rat. Many show validated cross-reactivity with additional species. Check the product datasheet for confirmed reactivity data.

Какова ваша политика замены?

If a product does not perform as described under recommended conditions, contact us within 30 days for replacement or credit. Our technical team will help troubleshoot first.

Могу ли я заказать пользовательские антитела?

Yes — our parent company AtaGenix offers full custom antibody development from immunogen design through hybridoma screening and scale-up production.